Development and validation of a nomogram combining PI-RADS v2.1 and clinical indicators for the diagnosis of prostate cancer in patients with PSA ≤ 20 ng/mL

The PI-RADS v2.1 assessment derived from biparametric MRI demonstrates standalone prognostic value for detecting prostate malignancies in patients with serum PSA concentrations below 20 ng/mL. This imaging-based scoring system, when integrated with additional clinical parameters, significantly enhances the diagnostic reliability of clinical assessments. The methodology provides clinicians with a non-invasive evaluation tool featuring intuitive visualization capabilities, potentially reducing the necessity for invasive biopsy procedures while maintaining diagnostic precision. This integrated methodology demonstrates considerable promise as an effective framework for improving diagnostic accuracy in PCa identification and supporting therapeutic choices in clinical practice.